COST-EFFECTIVENESS ANALYSIS OF INSULIN, SULFONYLUREA, AND SULFONYLUREA– METFORMIN IN TYPE 2 DIABETES MELLITUS


Endang Laelasari, Rani Sauriasari, Agusdini Banun

Abstract


Objective: This study aims to compare the cost-effectiveness of insulin therapy, sulfonylureas, and combination of sulfonylureas-metformin in patients with type 2 diabetes mellitus in Sitanala Hospital, Tangerang.

Methods: This study employed a cross-sectional to examine the effectiveness and cost of different treatments for Type 2 diabetes mellitus (T2DM) among outpatients at Dr. Sitanala Leprosy Hospital in Tangerang, using cost-effectiveness analysis. Participants had consumed the same drug over the past 4 months and were divided into three groups, as follows: An insulin group (n=29), sulfonylurea group (n=29), and sulfonylurea–metformin combination group (n=39). The effectiveness of treatment was evaluated by considering Hemoglobin A1c (HbA1c) values. The measured cost was direct medical cost.

Results: The results showed that there were more female patients (65.96%) than male patients with T2DM, and their average age was 50-59 years. The highest effectiveness was shown in combination in the sulfonylurea–metformin group, with an HbA1c level of 7.48±1.89, although the difference was not statistically significant. The direct medical cost of sulfonylurea monotherapy was significantly lower than that of the other therapies. The average cost-to-effectiveness ratio in the insulin group was Rp. 40,866 that in the sulfonylurea group was Rp. 1,369 and that in the combination of sulfonylurea–metformin group was Rp. 2,621 per percentage of effectivity. The incremental cost-to-effectiveness ratio for the sulfonylurea–metformin to sulfonylurea monotherapy treatment was Rp. 16,194 per percentage effectivity.

Conclusion: Based on the analysis performed, sulfonylurea–metformin combination therapy was more cost-effective than either sulfonylurea or insulin monotherapy.


Keywords


Type 2 diabetes mellitus, Analysis of cost-effectiveness, Antidiabetes.

| PDF |

References


Renuga E, Ramakrishnan SR, Vanitha RN, Thennarasu P, Kannan G. Impact of continuous patient counselling on knowledge, attitude, and practices and medication adherence of diabetec patients attending outpatient pharmacy services. Asian J Pharm Clin Res 2016;9(1):364-9.

International Diabetes Federation. IDF Diabetes Atlas. 7th ed. International Diabetes Federation; 2015.

Keban SA, Najuah N, Abdillah S. The role of pharmacyst in evaluating and intervening the patients with diabetic neuropathy. Asian J Pharm Clin Res 2017;10(2):127-31.

Indonesian Ministry of Health. Peraturan Mentri Kesehatan Republik Indonesia Nomor 59 Tahun 2014 Tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Jaminan Kesehatan. Jakarta: Indonesian Ministry of Health; 2014.

Sitanala RD. Laporan Tahunan Tahun Anggaran 2014 Instalasi Rawat Jalan. Tangerang: RSK Dr. Sitanala; 2014.

Wahyuni NK, Larasathy LP, Udayani NN. Analisis Efektivitas Biaya Penggunaan Terapi Kombinasi Insulin dan Oho Pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan di RSUD Wangaya. Bali: Universitas Udayana; 2012.

Primadiamanti A, Andayani TM. Analisis efektifitas biaya penggunaan insulin di bandingkan kombinasi insulin-metformin pada pasien diabetes melitus Tipe 2. J Farmasi Indones 2009;4:146-55.

Abdelaziz MS, Rani HS, Ravindranath S, Shaik R, Kasim M, Salam AA. Pharmacoeconomic evaluation of oral-hypoglicemic agent at hospital in Bangalore. IOSR J Pharm Biol Sci 2015;10:46-50.

Bootman JL, Townsand RJ, McGhan WF. Prinsiples of Pharmacoeconomics. Cincinnati, OH: Harvey Whitney Books Company; 1996.

Arnold RJ. Drugs Discovery Series No. 13: Pharmacoeconomics from Theory to Practice. New York: CRC Press; 2010.

Meneilly G. Pathophysiology of Diabetes in Elderly. United Stated of America: American Society of Health-System Pharmacists Inc.; 2010.

Diabetes Care. American Diabetes Association: Standard of medical care in diabetes 2016. J Clin Appl Res Educ 2016;30 Suppl 1:S1-10.

Sangam K, Anifa M, Swathi K, Venkateswarlu K, Reddy TR. Evaluation of pharmacoeconomic direct cost in diabetes patients. Asian J Pharm Clin Res 2017;10(4):38-40.




About this article

Title

COST-EFFECTIVENESS ANALYSIS OF INSULIN, SULFONYLUREA, AND SULFONYLUREA– METFORMIN IN TYPE 2 DIABETES MELLITUS

Keywords

Type 2 diabetes mellitus, Analysis of cost-effectiveness, Antidiabetes.

DOI

10.22159/ajpcr.2017.v10s5.23094

Date

01-10-2017

Additional Links

Manuscript Submission

Journal

Asian Journal of Pharmaceutical and Clinical Research
Special Issue October 2017 [PTMDS 2017] Page: 50-53

Print ISSN

0974-2441

Online ISSN

2455-3891

Statistics

0 Views | 0 Downloads

Authors & Affiliations

Endang Laelasari
Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
Indonesia

Rani Sauriasari
Department of Procurement Services, Sitanala Hospital, Tangerang, Indonesia.
Indonesia

Agusdini Banun
Directorate General of Pharmacy and Medical Devices, Ministry of Health, Indonesia.
Indonesia


Article Tools


Email this article (Login required)
Email the author (Login required)

Refbacks

  • There are currently no refbacks.